Cambridge University Hospitals group launches experimental drug trial to treat Covid-19
Cambridge University Hospitals group is launching a fast-turnaround experimental drug trial to treat Covid-19.
Two new treatments which tackle aspects of the coronavirus infection are to be tested in the innovative trial which will respond quickly to results from small numbers of patients.
The newly launched trial, known as TACTIC-E (the “E” stands for “experimental”), has been designed to test drugs that have been specifically developed to treat Covid-19 as well as investigating whether combinations of drugs that are already in use can be effective.
The trial will determine whether the major organ complications in severe Covid-19 can be reduced (or prevented) by targeting previously unexplored pathways, via the gut, to reduce the inflammatory response, and via the inner lining of blood vessels, to help increase the amount of oxygen available in the lungs.
One of the drugs to be used in the trial is called EDP1815. The other arm of the trial will involve using two drugs in combination: Dapagliflozin and Ambrisentan.
For more information visit: ITV News
Published May 22, 2020
Latest from CCTU
Research sets global standard for Crohn’s treatment
Trial results published by Cambridge researchers earlier this year and involving patients at Addenbrooke’s Hospital are helping to set new global standards…
Team praised for “game-changing” heart trial
A senior Addenbrooke’s early phase trials researcher has praised patients, staff and sponsors who backed a landmark trial which could be a “game changer” in…
Improving outcomes for Crohn's patients
Treating newly-diagnosed patients with advanced therapy leads to dramatic improvements in outcomes.
